多发性骨髓瘤患者骨髓中BAFF的含量及B细胞表面BAFF受体表达的研究  

BAFF Level in Bone Marrow and Expression of BAFF Receptor on B Cells in Multiple Myeloma Patients

作　　者：周振海[1] 张玲[1] 潘倩影[1] 黄蓓辉[1] 郑冬[1] 刘俊茹[1] 李娟[1] 罗绍凯[1] 

机构地区：[1]中山大学附属第一医院血液内科,广东广州510080

出　　处：《中国实验血液学杂志》2012年第5期1131-1134,共4页Journal of Experimental Hematology

基　　金：广东省科技计划项目;编号2010B080701058;中国医师协会临床医学科研专项资金-血液肿瘤临床研究资金项目;编号20100104

摘　　要：本研究旨在分析多发性骨髓瘤(MM)患者骨髓中B细胞活化因子(BAFF)、增殖诱导配体(APRIL)的含量,B细胞、初始B细胞和记忆B细胞表面BAFF受体的表达,以探讨MM骨髓中B细胞的特点。采用流式细胞术检测19例初治MM(初治组)、17例平台期MM(平台期组)、10例对照组骨髓中B细胞(CD19+)、初始B细胞(CD19+IgD+)、记忆B细胞(CD19+CD27+)的表面BAFF受体(BAFF-R、TACI)的表达,ELISA法测定各组骨髓上清中BAFF、APRIL的含量。分析各组结果数据的差异及它们之间的相互关系。结果表明,初治组患者CD19+细胞表面BAFF-R受体表达明显高于平台期组和对照组;初治组患者CD19+IgD+细胞表面BAFF-R受体表达与平台期组无差别,但明显高于对照组;初治组患者CD19+CD27+细胞表面BAFF-R受体表达明显高于平台期组和对照组;各种B细胞表面BAFF-R受体表达在平台期组与对照组之间无差别;TACI受体表达总体水平低,初治组患者与平台期组、对照组比较,CD19+细胞、CD19+IgD+细胞、CD19+CD27+细胞表面TACI受体表达均无明显差异;初治组骨髓上清中BAFF含量明显高于平台期组和对照组,但平台期组与对照组间无明显差异;各组骨髓中APRIL的含量均无明显差异。结论:MM患者骨髓中BAFF含量增高,CD19+细胞、CD19+IgD+细胞和CD19+CD27+细胞表面BAFF受体的表达均增加,这可能有助于促进B细胞的增殖,因而可能与MM发病机制有关。This study was purposed to investigate the B cell-activating factor belonging to the TNF family（BAFF） and a proliferation-inducing ligand（APRIL） levels in bone marrow,and the BAFF receptor expression level on B cells in multiple myeloma（MM） patients,in order to explore the characteristics of B cells in bone marrow of MM patients.MM patients were studied before treatment（newly diagnosed group,19 patients） and after treatment with improvement（stable group,17 patients）,10 non-hematologic patients were selected as control（control group）.The BAFF receptors（BAFF-R） and transmembrane activator and calcium modulator and cyclophilin ligand interactor（TACI） on B cell（CD19＋）,naive B cell（CD19＋IgD＋） and memory B cell（CD19＋CD27＋） of bone marrow in all groups were detected by flow cytometry.The BAFF,APRIL level in bone marrow supernatant were tested with ELISA.The results showed that the BAFF-R expression level on CD19＋ cells in newly diagnosed group were higher than that in stable group and control group;there was no significant difference between the BAFF-R expression level on CD19＋IgD＋ cells in newely diagnosed group and stable group,but BAFF-R expression level on CD19＋IgD＋ cells in newely diagnosed group was higher than that in control group;the BAFF-R expression level on CD19＋CD27＋ cells in newely group was higher than that in stable group and control group;there was no significant difference between the BAFF-R expression level on CD19＋ cells,CD19＋IgD＋ cells or CD19＋CD27＋ cells in stable group and control group.There was no significant difference among the TACI expression level on CD19＋ cells,CD19＋IgD＋ cells or CD19＋CD27＋ cells in newly diagnosed group,stable group and control group.The bone marrow supernatant BAFF level in nwely diagnosed group was higher than that in stable group and control group,but there was no significant difference between stable group and control group.There was no significant difference among the bone marrow T

关 键 词：多发性骨髓瘤 B细胞 B细胞活化因子 B细胞活化因子受体 

分 类 号：R733.3[医药卫生—肿瘤]